Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies

Acta Cardiologica

Volumn 58, Issue 5, 2003, Pages 403-410

  Thijs, Lutgarde ^a,c   Fagard, Robert ^a   Forette, Françoise ^b   Nawrot, Tim ^a   Staessen, Jan A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Paris Descartes University   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cardiovascular diseases; Dehydroepiandrosterone sulphate (DHEAS); Review

Indexed keywords

PRASTERONE SULFATE;

ADULT; AGE DISTRIBUTION; AGED; BLOOD; CALCULATION; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; MORTALITY; PREDICTION AND FORECASTING; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0142089874     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.58.5.2005304     Document Type: Review

References (54)

1. Ebeling P, Koivisto VA. Physiologic importance of dehydroepiandrosterone. Lancet 1994; 343: 1479-81.
2. Hornsby PJ. DHEA: a biologist's perspective. J Am Geriatr Soc 1997; 45: 1395-401.
3. Vermeulen A. Dehydroepiandrosterone sulfate and aging. Ann N Y Acad Sci 1995; 774: 121-7.
4. Hendrikx A. Influence of a low-calorie diet and fasting on the metabolism of dehydroepiandrosterone sulfate in adult obese subjects. J Clin Endocrinol Metab 1968; 28: 1525-33.
5. Meldrum DR, Davidson BJ, Tafaryn IV, Judd HL. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981; 57: 624-8.
6. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59: 551-5.
7. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016-25.
8. Orentreich N, Brind JL, Vogelman J, Andres R, Baldvin H. Long-term longitudinal measurements of plasma dehydroepiandrosteron sulfate in normal men. J Clin Endocrinol Metab 1992; 75: 1002-4.
9. Mazat L, Lafont S, Berr C, Debuire B, Tessier J-F, Dartigues J-F Baulieu EE. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci USA 2001; 98: 67-9.
10. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999; 39: 327-48.
11. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125: 1-13.
12. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. J Clin Invest 1988; 82: 712-20.
13. Okamoto K. Distribution of dehydroepiandrosterone sulfate and relationships between its level and serum lipid levels in a rural Japanese population. J Epidemiol 1998; 8: 285-91.
14. Abbasi A, Duthie EHJ, Sheldahl L, Wilson C, Sasse E, Rudman I, Mattson DE. Association of dehydroepiandrosterone sulfate, body composition, and physical fitness in independent community-dwelling older men and women. J Am Geriatr Soc 1998; 46: 263-73.
15. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body, fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66: 57-61.
16. Shono N, Kumagai S, Higaki Y, Mishizumi M, Sasaki H. The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men. J Atheroscler Thromb 1996; 3: 45-51.
17. Haffner SM, Valdez RA, Mykkänen L, Stern MP, Katz S. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994; 43: 599-603.
18. Paolisso G, Ammendola S, Rotondi M, Gambardella A, Rizzo MR, Mazziotti G, Tagliamonte MR, Carella C, Varricchio M. Insulin resistance and advancing age: what role for dehydroepiandrosterone sulfate? Metabolism 1997; 46: 1281-6.
19. Daynes RA, Araneo BA, Ershler WB. Altered regulation of IL-6 production with normal aging: possible linkage to the age-associated decline in dehydroepiandrosterone and its sulphate derivative. J Immunol 1993; 150: 5219-30.
20. Zumoff B, Troxler RG, O'Connor J, Rosenfeld RS, Kream J, Levin, Sloan AM, Walker W, Cook RL, Fukushima DK. Abnormal hormone levels in men with coronary artery disease. Atherosclerosis 1982; 2: 58-67.
21. Slowinska-Srzednicka J, Zgliczynski S, Ciswicka-Sznajderman M, Srzednicki M, Soszynski P, Biernacka M, Woroszylska M, Ruzyllo W, Sadowski Z. Decreased plasma dehydroepiandrosterone sulfate and dehydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis 1989; 79: 197-203.
22. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM, Rao DC. Evidence for an association between dehydroepiandrosterone sulfate and non-fatal, premature myocardial infarction in males. Circulation 1994; 89: 89-93.
23. Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO, Pearson TA. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnositic coronary angiography. J Am Coll Cardiol 1990; 16: 862-70.
24. Adamkiewicz M, Zgliczynski S, Slowinska-Srzednicka J, Pietrzyk E, Rabijewski M, Srzednicki M, Gardas A, Sadowski Z. The relationship between plasma androgens (dehydroepiandrosteron sulfate and testosterone) and coronary arteriosclerosis in men: the lower the androgens, the higher the coronary score of arteriosclerosis. The Aging Male 1999; 2: 22-32.
25. Hauner H, Stangl K, Burger K, Busch U, Blomer H, Pfeiffer EF. Sex hormone concentration in men with angiographically assessed coronary artery disease - relationship to obesity and body fat distribution. Klin Wochenschr 1991; 69: 664.
26. Berr C, Lafont S, Debuire B, Dartigues J-F, Baulieu E-E. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci USA 1996; 93: 13410-5.
27. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts male aging study. Am J Epidemiol 2001; 153: 79-89.
28. Hautanen A, Mänttäri M, Manninen V, Tenkanen L, Huttunen JK, Frick MH, Adlercreutz H. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 1994; 105: 191-200.
29. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 1990; 11: 460-70.
30. Schaefer C, Friedman G, Ettinger B, Quesenberry C, Liu J, Haan M, Orentreich N, Vogelman J. Dehydroepiandrosterone sulfate (DHEAS), angina, and fatal ischemic heart disease. Am Epidemiol 1996; 143, S69. [Abstract].
31. Trivedi DP, Khaw K-T. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 2001; 86: 4171-7.
32. LaCroix AZ, Yano K, Reed DM. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 1992; 86: 1529-35.
33. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ. Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am J Epidemiol 1994; 140: 870-5.
34. Hedges LV, Olkin I. Combining estimates of correlation coefficients. Statistical methods for meta-analysis, pp 229-36. San Diego: Academic Press, Inc., 1985.
35. Rudman D, Shetty KR, Mattson DE. Plasma dehydroepiandrosterone sulfate in nursing home men. J Am Geriatr Soc 1990; 38: 421-7.
36. Tilvis RS, Kähönen M, Härkönen M. Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging Clin Exp Res 1999; 11: 30-4.
37. Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 1995; 91: 1757-60.
38. Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Ann N Y Acad Sci 1995; 29: 259-70.
39. Legrain S, Berr C, Frenoy N, Gourlay V, Debuire V, Baulieu E-E. Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 1995; 41: 343-51.
40. Nafziger AN, Herrington DM, Bush TL. Dehydroepiandrostereone and dehydroepiandrosterone sulphate: their relation to cardiovascular disease. Epidemiologic Reviews 1991; 13: 267-93.
41. Levy HR. Glucose-6-phosphate dehydrogenase. Adv Enzymol 1979; 48: 97.
42. Lopez SA, Wingo C, Hebert JA. Total serum cholesterol and urinary dehydroepiandrosterone in humans. Atherosclerosis 1976; 24: 471.
43. Haffner SM, Mykkänen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77: 1610-5.
44. Nestler JE, Clore JN, Blackard WG. Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J 1992; 6: 3073-5.
45. Tchernof A, Labric F, Belanger A. Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. J Endocrinol 1996; 150: S155-S164.
46. Demirgoren S, Majewska MD, Spivak CE. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABA receptor. Neuroscience 1991; 45: 127-35.
47. Barrett-Connor E, Khaw K-T. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 1987; 317: 711.
48. Khaw K-T. Dehydroepiandrosterone, dehydroepiandroterone sulphate and cardiovascular disease. J Endocrinol 1996; 150: S149-S153.
49. Fassati P, Fassati M, Sonka J. Dehydroepiandrosterone sulfate - a new approach to some cases of angina pectoris therapy. Aggressologie 1970; 11: 445-8.
50. Mortola J, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71: 696-704.
51. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement does of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360-7.
52. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998; 49: 421-32.
53. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, Buster J E. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high density lipoprotein: a six-month trial. Fertil Steril 1998; 70: 107-10.
54. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel J, Kapoor S, Nestler JE. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84: 3896-902.